Wegovy Reviews: What Real Patients Say About Results, Fatigue, and the Lawsuits

What do Wegovy reviewers actually say, overall?

On Drugs.com — one of the largest public patient-review pools for any prescription drug — Wegovy currently sits at 7.3 out of 10 across roughly 716 reviews, with about 62% of reviewers reporting a positive experience and 17% reporting a negative one. That's a genuinely strong showing, and it's specifically about the branded, FDA-approved pen: Drugs.com organizes reviews by product name, so what you're reading there is the experience of people who filled an actual Wegovy prescription, not compounded semaglutide from a telehealth membership.

Reddit tells a similar story with more texture and less arithmetic. Communities built around Wegovy specifically, plus the broader semaglutide and weight-loss subreddits where Wegovy users post alongside everyone else, run on a fairly stable set of recurring threads rather than one definitive post: the rough first few weeks on the lowest dose, the moment appetite and "food noise" seem to switch off, monthly progress updates timed to dose changes, plateau and stall complaints, and a steady undercurrent of insurance and prior-authorization frustration that has nothing to do with how the drug performs biologically. No single thread stands in as the definitive account of any one claim — that's simply how a forum with years of posts behind it works, with the signal living in the accumulation rather than one viral thread.

One thing worth separating out early: if what you're actually weighing is the compounded or generic semaglutide route rather than the brand-name pen, the pricing, legal status, and review landscape there are different enough to deserve their own conversation — see semaglutide reviews for that angle, rather than a footnote on this one.

3-month results: what reviewers actually lost, and when it kicked in

The number reviewers cite most often when they post a "3 month update" lines up closely with what Novo Nordisk's own STEP 1 trial found. At week 12 — the three-month mark — participants on semaglutide 2.4mg averaged 9.6% weight loss, against 2.8% on placebo. That builds on a smaller early move: by week 4, the average was already 3.8%. It keeps climbing well past the three-month point too, reaching about 13.8% at six months and 14.9% by week 68, the trial's full length.

Here's the detail most "3 month results" posts leave out, and it matters: under the FDA-approved dosing schedule, nobody reaches the 2.4mg maintenance dose until week 17 at the earliest. That means the trial's own three-month number, and most real reviewers' three-month number, reflects someone still climbing the ladder — likely sitting at the 1mg step, not yet at a full treatment dose. A three-month result is a preview of what the escalation period does, not a ceiling on what the drug can do once someone's actually at maintenance for a while.

The side effects reviewers mention most — fatigue tops the list

By the numbers, nausea is Wegovy's single most common side effect: 44% of STEP 1 participants reported it, against 16% on placebo, with diarrhea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%) following behind. Fatigue sits on the FDA label too, among the adverse reactions reported by at least 5% of trial participants, though the label doesn't break out an exact percentage for it the way it does for the GI symptoms above.

What's interesting is the gap between that official ranking and what reviewers actually complain about longest. Nausea tends to spike hard in the days right after a dose increase and then fade within a week or two. Fatigue, in a lot of real accounts, doesn't follow that same clean curve — it lingers through the days that aren't right after an injection too, which is probably why "wegovy fatigue" shows up in searches nearly as often as the more clinically prominent nausea does. The likely explanation isn't a hidden drug effect so much as simple math: eating meaningfully less, for weeks at a stretch, tends to produce tiredness on its own, on top of whatever the GI symptoms are already costing in sleep and appetite.

For the full breakdown of what's ordinary titration discomfort versus what's a same-day concern — including the rarer but more serious risks like gallbladder disease and the thyroid boxed warning — Wegovy's full side-effects guide covers it in one place rather than repeating it here.

Does the dose you're on change your review?

Enormously, and it's the single biggest reason two Wegovy reviews can read like they're describing different drugs. A review written two weeks into the 0.25mg starting dose is almost always underwhelmed — that dose exists purely for tolerability, not results, and isn't expected to move the scale much. Reviews from people well into 1.7mg or 2.4mg read differently: stronger results, but also where most of the GI-symptom complaints concentrate, since side effects generally track with how much the drug is actually doing.

There's no FDA-approved 5mg strength of Wegovy — the real ladder runs 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg as the standard maintenance dose. Searches for "wegovy 5mg reviews" are almost certainly a mix-up with 0.5mg or a rounded mention of the 2.4mg ceiling; there's nothing at 5mg to review. A newer, higher-strength option, Wegovy HD at 7.2mg, was reportedly FDA-approved in March 2026 for people who've already plateaued on 2.4mg — not a starting or early option (this is a fast-moving regulatory detail worth double-checking directly against FDA.gov before relying on it). The trial behind that approval reported roughly 21% average weight loss at 72 weeks, a meaningfully bigger number than 2.4mg alone typically produces, alongside more frequent reports of skin-related sensations like tingling or heightened sensitivity at that dose. Early "wegovy 7.2 reddit" posts reflect a genuinely newer, smaller pool of reviewers than the years of 2.4mg commentary already out there, so treat any single account of the HD dose as less established than the broader 2.4mg review base.

The lawsuits mentioned alongside these reviews — what's actually pending

It's a fair question to bring to any review thread, and worth answering plainly rather than either ignoring it or overstating it. Thousands of federal lawsuits alleging gastroparesis and related severe gastrointestinal injury from GLP-1 drugs, Wegovy among them, are consolidated into a multidistrict litigation in the Eastern District of Pennsylvania — MDL 3094, with roughly 3,928 cases pending there as of August 2026. A separate, newer multidistrict litigation, created in December 2025, consolidates more than 100 federal claims alleging a link between GLP-1 drugs and NAION, a rare form of sudden vision loss; a parallel set of state-court cases has also been consolidated in New Jersey.

As of this writing, the gastroparesis litigation is in active pretrial proceedings — case counts and the exact procedural stage move fast enough that they're worth a fresh check right before you read this — with no bellwether verdict or settlement reached in either track. Both Novo Nordisk and Eli Lilly continue to deny liability. None of this amounts to a safety recall: Wegovy remains fully FDA-approved, its label already discloses GI risk, and this litigation is specifically about whether the warnings on that label were adequate — a legal question still being argued, not a settled finding that the drug caused anyone's injury.

How do these reviews compare to the clinical trial numbers?

The two measure genuinely different things, which is easy to forget when a percentage from each shows up in the same sentence. A trial figure like STEP 1's 44% nausea rate comes from a fixed, controlled population followed on a set schedule, counting every reported adverse event regardless of severity. A Drugs.com rating or a Reddit post is self-selected — people who felt strongly enough, in either direction, to sit down and write something — which tends to amplify both the best and worst experiences relative to the quiet middle.

Even with that difference in mind, the two datasets land closer together than you might expect. Roughly 6.8% of Wegovy trial participants stopped treatment altogether because of a side effect, against Drugs.com's 17% negative-review share — not the same number, but not wildly out of step either, once you account for "negative review" capturing frustration well short of quitting, like a slower-than-hoped result or an insurance hassle that had nothing to do with the medication itself.

Reading these reviews as a woman 40+: what overlaps with perimenopause, and what doesn't

A detail worth knowing before you read too much into any one Wegovy review: sex-disaggregated data from Wegovy's own Phase 3 trial program found 90.5% of women reported some adverse event, against 83.4% of men — a gap that tracks with women also losing more weight on average in those same trials, not a sign the drug behaves less safely in women's bodies specifically.

Where it gets genuinely harder to untangle is in your forties. Fatigue, disrupted sleep, and stomach upset already show up on their own during the menopause transition, with no medication involved at all, so a review from a woman starting Wegovy at 45 is often describing two overlapping symptom sets at once rather than one clean drug effect. GI symptoms that track tightly with each dose increase and settle within a week or two are more likely the medication; fatigue or mood shifts that show up independent of dosing, or alongside hot flashes and cycle changes, are more likely the menopause transition running in parallel. Nobody has published a trial that breaks Wegovy's side-effect profile down by menopausal status specifically, which means this distinction is something you and a reviewer both have to reason through, not something a study has already sorted out. Wegovy's side-effects guide goes further into the bone- and muscle-related considerations that matter more past 40, and how the drug actually works is worth a read if the mechanism behind any of this is still fuzzy.

Bottom line: is Wegovy worth it, based on real reviews?

Taken together, the review record backs up what the trial data already suggested, with some real texture added on top: most people who stick with Wegovy land somewhere positive, a meaningful three-month result is realistic even before reaching a full maintenance dose, and the complaints that dominate real accounts — GI symptoms early on, fatigue that lingers a bit longer than expected — are consistent enough across thousands of reviewers to plan around rather than dismiss as bad luck. The lawsuits are worth knowing about as a legitimacy check on the manufacturer's conduct, not a reason to assume the drug itself has failed anyone; that's still an open legal question.